2025 China Antibiotic Resistance Market Revenue Opportunities Report
Description
The 2025 China Antibiotic Resistance Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibiotic Resistance Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antibiotic resistance market in China include Pfizer, AstraZeneca, Merck & Co., and AbbVie. Pfizer has partnered with Shanghai-based Zai Lab to market the antibacterial drug Xacduro in mainland China, targeting drug-resistant bacteria like Acinetobacter baumannii, a critical pathogen in the region. AstraZeneca faces challenges but remains a significant player with its portfolio and R&D in antimicrobial agents. Merck and AbbVie are key global antibiotic developers investing in novel agents to address resistance, and both have a presence in China’s expanding market.
These companies are capitalizing on China’s growing antibiotic resistance market, which generated approximately USD 852.2 million in 2023 and is projected to reach USD 1.26 billion by 2030, growing at a 5.7% CAGR. The urgency in China stems from high rates of resistant infections, especially carbapenem-resistant Acinetobacter baumannii with resistance rates reaching 74%. These firms are advancing antibiotic innovation and collaborating with local biotechs, reflecting China’s strategic importance in global antimicrobial resistance efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibiotic Resistance Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in the antibiotic resistance market in China include Pfizer, AstraZeneca, Merck & Co., and AbbVie. Pfizer has partnered with Shanghai-based Zai Lab to market the antibacterial drug Xacduro in mainland China, targeting drug-resistant bacteria like Acinetobacter baumannii, a critical pathogen in the region. AstraZeneca faces challenges but remains a significant player with its portfolio and R&D in antimicrobial agents. Merck and AbbVie are key global antibiotic developers investing in novel agents to address resistance, and both have a presence in China’s expanding market.
These companies are capitalizing on China’s growing antibiotic resistance market, which generated approximately USD 852.2 million in 2023 and is projected to reach USD 1.26 billion by 2030, growing at a 5.7% CAGR. The urgency in China stems from high rates of resistant infections, especially carbapenem-resistant Acinetobacter baumannii with resistance rates reaching 74%. These firms are advancing antibiotic innovation and collaborating with local biotechs, reflecting China’s strategic importance in global antimicrobial resistance efforts.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
